Key result
Childhood ALL survivors exhibit ~11% higher plasma ADMA levels than healthy controls.
Why the study?
Are plasma levels of ADMA elevated in young adult survivors of childhood ALL compared to healthy controls?
Case-Control (n=45)
Are plasma levels of ADMA elevated in young adult survivors of childhood ALL compared to healthy controls?
Young adult survivors of childhood ALL exhibit subtle elevations in the cardiovascular risk biomarker ADMA, which may be partially related to minor lipid profile changes.
Answers are grounded in this paper and cite their sources.
Elevated ADMA in ALL survivors may indicate CV risk; leaves open whether it predicts events or warrants intervention.
BACKGROUND: Adult survivors of childhood malignancy are predisposed to late cardiovascular (CV) complications. Our aim was to estimate plasma levels of the endogenous nitric oxide formation inhibitor asymmetric dimethylarginine (ADMA), in long-term survivors of childhood acute lymphoblastic leukemia (ALL) treated with only chemotherapy. METHODS: ADMA and its isomer symmetric dimethylarginine (SDMA) were measured in 25 former ALL patients (aged 18-28 years) who had survived without recurrent disease ≥ 5 years from completing chemotherapy without cranial irradiation, and in 20 healthy controls (aged 20-31 years). RESULTS: Characteristics of the both groups were similar, except for lower high-density lipoproteins-cholesterol (HDL-C) in ALL survivors. Compared to controls, the former ALL patients exhibited significant, albeit small, rises in levels of ADMA (0.63 ± 0.09 [SD] vs. 0.57 ± 0.07 μmol/L; p=0.016), but not SDMA, with a consequently increased ADMA to SDMA ratio (1.08 ± 0.22 vs. 0.91 ± 0.16; p=0.004). The effect of former ALL on ADMA was attenuated (intergroup p=0.10 [ANCOVA]) upon adjustment for HDL-C (ADMA vs. HDL-C regression coefficient: -0.065 ± 0.030 [SEM]; p=0.03). CONCLUSIONS: ADMA is elevated in adult childhood ALL survivors, which can reflect late detrimental chemotherapy effects, partially related to minor lipid profile changes. Whether these subtle ADMA elevations might herald future CV morbidity, remains to be elucidated.
No takes yet. Share an insight, caveat, or question.
Sulicka‐Grodzicka et al. (2012) conducted a case-control in Childhood acute lymphoblastic leukemia (ALL) survivors (n=45). History of childhood acute lymphoblastic leukemia vs. Healthy controls was evaluated on Plasma levels of asymmetric dimethylarginine (ADMA) (p=0.016). Long-term survivors of childhood acute lymphoblastic leukemia exhibited significantly higher plasma ADMA levels compared to healthy controls (0.63 vs. 0.57 μmol/L; p=0.016).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: